Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | DHODH | Q02127 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3174133 | 0.94 | GRIN2B (0.46) | GRIN2BRAB9ANPC1ALDH1A1MALT1 | |
| SCHEMBL8459936 | 0.82 | ADRA2A (0.54) | GRIN2BRAB9ANPC1ALDH1A1MAPT | |
| SCHEMBL8446323 | 0.81 | ADRA2A (0.53) | GRIN2BRAB9ANPC1ALDH1A1GAA | |
| SCHEMBL8451960 | 0.79 | ALDH1A1 (0.53) | RAB9ANPC1ALDH1A1MAPTLMNA | |
| Trifluoroacetic Acid SCHEMBL3174860 | 0.76 | ADRA2A (0.49) | GRIN2BRAB9ANPC1ALDH1A1GAA | |
| Trifluoroacetic Acid SCHEMBL3177374 | 0.76 | DHODH (0.48) | RAB9ANPC1ALDH1A1DHODHMAPT | |
| Trifluoroacetic Acid SCHEMBL3179359 | 0.75 | EGLN1 (0.48) | GRIN2BRAB9ANPC1ALDH1A1GAA | |
| Trifluoroacetic Acid SCHEMBL3169886 | 0.74 | PDK2 (0.51) | GRIN2BRAB9ANPC1ALDH1A1MAPT | |
| SCHEMBL5013538 | 0.74 | ALDH1A1 (0.64) | RAB9ANPC1ALDH1A1MALT1CHRM2 | |
| SCHEMBL3177382 | 0.74 | DHODH (0.43) | DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188291-B2 | Heteroaryl-substituted carboxamides and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| US-8188291-B2 | Heteroaryl-substituted carboxamides and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| US-20100016337-A1 | HETEROARYL-SUBSTITUTED CARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-01-21 | — | — | US | disclosed |
| US-20100016337-A1 | HETEROARYL-SUBSTITUTED CARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-01-21 | — | — | US | disclosed |
| WO-2008077507-A1 | HETEROARYL-SUBSTITUTED CARBOXAMIDES AND USE THEREOF FOR THE STIMULATION OF THE EXPRESSION OF NO SYNTHASE | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | WO | disclosed |
| EP-1939181-A1 | Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase | sanofi-aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016337-A1 | HETEROARYL-SUBSTITUTED CARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | TBXAS1, PTGIS, NOS2 | GRIN2B 2255/4885RAB9A 3124/4885NPC1 2911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.